Table 5.
Odds ratios (95% CI) for ovarian cancer for doubling in CRP and IL-6 by BMI categories and waist circumference*
| CRP | IL-6 | ||||
|---|---|---|---|---|---|
| ORlog2 (95% CI) | phet1 | ORlog2 (95% CI) | phet1 | ||
| BMI <25 | |||||
| All Sets | (345 sets) | 0.98 (0.88 - 1.08) | 1.06 (0.88 - 1.28) | ||
| Serous tumors | (216 sets) | 0.97 (0.84 - 1.11) | 0.89 (0.70 - 1.14) | ||
| Non-serous tumors | (135 sets) | 0.98 (0.84 - 1.13) | 1.36 (1.01 - 1.82) | ||
| Type II tumors | (151 sets) | 0.98 (0.83 - 1.15) | 0.72 (0.51 - 1.00) | ||
| BMI ≥25 | |||||
| All Sets | (363 sets) | 1.09 (0.98 - 1.20) | 0.12 | 1.12 (0.92 - 1.35) | 0.05 |
| Serous tumors | (187 sets) | 1.10 (0.96 - 1.26) | <0.01 | 1.13 (0.86 - 1.48) | <0.01 |
| Non-serous tumors | (182 sets) | 1.07 (0.93 - 1.24) | 0.26 | 1.10 (0.84 - 1.44) | 0.18 |
| Type II tumors | (146 sets) | 1.00 (0.86 - 1.16) | 0.26 | 1.15 (0.85 - 1.56) | 0.06 |
| BMI <25 | |||||
| All Sets | (345 sets) | 0.98 (0.88 - 1.08) | 1.06 (0.88 - 1.28) | ||
| Serous tumors | (216 sets) | 0.97 (0.84 - 1.11) | 0.89 (0.70 - 1.14) | ||
| Non-serous tumors | (135 sets) | 1.07 (0.93 - 1.24) | 1.36 (1.01 - 1.82) | ||
| Type II tumors | (151 sets) | 0.98 (0.83 - 1.15) | 0.72 (0.51 - 1.00) | ||
| BMI 25-30 | |||||
| All Sets | (232 sets) | 1.06 (0.94 - 1.19) | 1.02 (0.81 - 1.27) | ||
| Serous tumors | (114 sets) | 1.01 (0.86 - 1.19) | 0.98 (0.70 - 1.38) | ||
| Non-serous tumors | (122 sets) | 1.10 (0.93 - 1.31) | 1.04 (0.77 - 1.40) | ||
| Type II tumors | (94 sets) | 0.93 (0.78 - 1.10) | 1.06 (0.73 - 1.55) | ||
| BMI ≥30 | |||||
| All Sets | (131 sets) | 1.25 (0.96 - 1.62) | 0.04 | 1.35 (0.82 - 2.23) | 0.74 |
| Serous tumors | (73 sets) | 1.25 (0.85 - 1.84) | 0.05 | 1.28 (0.68 - 2.41) | 0.03 |
| Non-serous tumors | (60 sets) | 1.26 (0.87 - 1.81) | 0.81 | 1.50 (0.67 - 3.35) | 0.28 |
| Type II tumors | (52 sets) | 1.18 (0.78 - 1.77) | 0.33 | 1.30 (0.66 - 2.57) | 0.07 |
| Waist ≤88 | |||||
| All Sets | (507 sets) | 0.94 (0.87 - 1.01) | 0.94 (0.82 - 1.09) | ||
| Serous tumors | (293 sets) | 0.92 (0.83 - 1.02) | 0.84 (0.69 - 1.02) | ||
| Non-serous tumors | (222 sets) | 0.97 (0.86 - 1.08) | 1.08 (0.88 - 1.33) | ||
| Type II tumors | (216 sets) | 0.88 (0.78 - 0.99) | 0.77 (0.60 - 0.98) | ||
| Waist >88 | |||||
| All Sets | (179 sets) | 1.26 (1.06 - 1.49) | 0.19 | 1.78 (1.28 - 2.48) | <0.01 |
| Serous tumors | (97 sets) | 1.38 (1.07 - 1.79) | 0.05 | 2.14 (1.33 - 3.45) | <0.01 |
| Non-serous tumors | (86 sets) | 1.16 (0.92 - 1.47) | 0.63 | 1.46 (0.91 - 2.34) | 0.51 |
| Type II tumors | (67 sets) | 1.26 (0.95 - 1.66) | 0.44 | 2.10 (1.20 - 3.67) | 0.04 |
| Waist ≤80 | |||||
| All Sets | (341 sets) | 0.93 (0.85 - 1.03) | 0.97 (0.81 - 1.16) | ||
| Serous tumors | (205 sets) | 0.92 (0.81 - 1.06) | 0.87 (0.68 - 1.11) | ||
| Non-serous tumors | (142 sets) | 0.94 (0.82 - 1.08) | 1.11 (0.85 - 1.43) | ||
| Type II tumors | (154 sets) | 0.91 (0.79 - 1.05) | 0.84 (0.62 - 1.13) | ||
| Waist 80-88 | |||||
| All Sets | (167 sets) | 0.99 (0.87 - 1.14) | 0.85 (0.66 - 1.11) | ||
| Serous tumors | (88 sets) | 0.93 (0.78 - 1.11) | 0.73 (0.49 - 1.08) | ||
| Non-serous tumors | (80 sets) | 1.11 (0.90 - 1.36 | 0.97 (0.67 - 1.42) | ||
| Type II tumors | (62 sets) | 0.87 (0.71 - 1.08) | 0.58 (0.35 - 0.96) | ||
| Waist >88 | |||||
| All Sets | (179 sets) | 1.26 (1.06 - 1.49) | 0.05 | 1.78 (1.28 - 2.48) | <0.01 |
| Serous tumors | (97 sets) | 1.38 (1.07 - 1.79) | 0.02 | 2.14 (1.33 - 3.45) | <0.01 |
| Non-serous tumors | (86 sets) | 1.16 (0.92 - 1.47) | 0.36 | 1.46 (0.91 - 2.34) | 0.14 |
| Type II tumors | (67 sets) | 1.26 (0.95 - 1.66) | 0.12 | 2.10 (1.20 - 3.67) | 0.03 |
| WHR <0.85 | |||||
| All Sets | (541 sets) | 0.96 (0.90 - 1.03) | 0.98 (0.86 - 1.13) | ||
| Serous tumors | (312 sets) | 0.94 (0.85 - 1.03) | 0.90 (0.74 - 1.08) | ||
| Non-serous tumors | (238 sets) | 0.98 (0.88 - 1.09) | 1.08 (0.89 - 1.32) | ||
| Type II tumors | (229 sets) | 0.86 (0.69 - 1.08) | 0.86 (0.69 - 1.08) | ||
| WHR ≥0.85 | |||||
| All Sets | (145 sets) | 1.18 (1.00 - 1.38) | 0.47 | 1.47 (1.09 - 1.99) | 0.03 |
| Serous tumors | (78 sets) | 1.22 (0.97 - 1.54) | 0.09 | 1.61 (1.04 - 2.51) | 0.01 |
| Non-serous tumors | (70 sets) | 1.12 (0.90 - 1.40) | 0.40 | 1.36 (0.91 - 2.04) | 0.52 |
| Type II tumors | (54 sets) | 1.21 (0.89 - 1.63) | 0.63 | 1.16 (0.66 - 2.04) | 0.34 |
All analyses conducted using conditional logistic regression retaining the matched sets; Cases and controls were matched for study center, age at blood donation, menopausal status, time of the day of blood collection, fasting status, exogenous hormone use at blood donation and menstrual cycle phase. Models adjust for BMI (continuous scale), ever full-term pregnancy (never/ever), age at first birth (continuous scale).
1
Statistical tests for heterogeneity were based on the likelihood-ratio test, comparing the model fit for logistic regression models with and without corresponding interaction term for the unadjusted and the multivariable model.